BACKGROUND: @entity1168 variability (HRV) and increased blood pressure variability ( @entity15882 ), determined in part by @entity842 (NO)-dependent @entity409 , are correlated with adverse prognosis in @entity65 . We examined potential alterations in @entity15882 and @entity74 , apolipoprotein (apo) E-/-, and control @entity19 and the effect of chronic @entity1780 treatment on these parameters in relation to their @entity17693 ( @entity17693 )-modifying properties. METHODS AND RESULTS: BP and HR were recorded in unrestrained, nonanesthetized @entity19 with implanted telemetry devices with or without @entity8671 . Cardiac and aortic expression of @entity13471 and caveolin-1 were measured by immunoblotting. Both systolic BP and HR were elevated in @entity6970 -/- @entity19 , with abolition of their circadian cycles. Spectral analysis showed an increase in their systolic @entity15882 in the very-low-frequency (+17%) band and a decrease in HRV in the high-frequency (-57%) band, reflecting @entity5433 . Decreased sensitivity to acute injection of @entity3897 or an @entity17693 inhibitor indicated basal alterations in both parasympathetic and @entity17693 regulatory systems in @entity6970 -/- @entity19 . Aortic caveolin-1 protein, an inhibitor of endothelial @entity17693 , was also increased in these @entity19 by 2.0-fold and correlated positively with systolic @entity15882 in the very-low-frequency band. @entity8671 treatment corrected the hemodynamic and caveolin-1 expression changes despite persisting elevated plasma @entity165 levels. CONCLUSIONS: @entity8671 decreases caveolin-1 expression and promotes @entity17693 function in @entity6970 -/-, dyslipidemic @entity19 in vivo, with concurrent improvements in @entity15882 and HRV. This highlights the beneficial effects of @entity8671 on cardiovascular function beyond those attributed to lipid lowering.

@entity8671 decreases caveolin-1 and improves @entity842 -dependent heart rate and blood pressure variability in XXXX -/- @entity19 in vivo.

@entity6970 :: ('11816(Tax:10090)', 'Gene') :: ['apoE'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin', 'Rosuvastatin'] @entity17693 :: ('18125(Tax:10090)', 'Gene') :: ['NO synthase', 'NOS'] @entity1780 :: ('CHEBI:35664', 'Chemical') :: ['statin'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity74 :: ('MESH:D030342', 'Disease') :: ['HRV in genetically dyslipidemic'] @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine'] @entity15882 :: ('10784', 'Species') :: ['BPV'] @entity5433 :: ('MESH:C563939', 'Disease') :: ['neurohumoral and autonomic dysfunction'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['Decreased heart rate'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases'] @entity13471 :: ('18127(Tax:10090)', 'Gene') :: ['endothelial NOS']
@entity6970 :: (11816(Tax:10090),Gene) :: ['apolipoprotein E']
